Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs 
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
Apple Turns 50: From Garage Startup to AI Crossroads 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth 
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
ROCKVILLE, Md., Aug. 31, 2017 -- REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced that it will present at the following September investor conferences:
Citi 12th Annual Biotech Conference
Dates: Wednesday, September 6 – Thursday, September 7
Location: Mandarin Oriental, Boston
Panel: Gene Therapy Manufacturing and Regulatory Opportunities and Challenges; Thursday, September 7, 2017 at 11:00 a.m. ET
Morgan Stanley 15th Annual Global Healthcare Conference
Dates: Monday, September 11 – Wednesday, September 13
Location: Grand Hyatt, New York
Fireside chat: Wednesday, September 13, 2017 at 11:05 a.m. ET
Cantor Fitzgerald Global Healthcare Conference
Dates: Monday, September 25 – Wednesday, September 27
Location: InterContinental New York Barclay Hotel, New York
Company presentation: Tuesday, September 26, 2017 at 4:00 p.m. ET
A live webcast of each presentation can be accessed in the Investors section of REGENXBIO’s website at www.regenxbio.com. An archived replay of each webcast will be available on the same website for approximately 30 days following the presentation. In addition, REGENXBIO senior management will be holding one-on-one meetings at each of the conferences.
About REGENXBIO
REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO’s NAV® Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas.
CONTACT: Investors Heather Savelle, 646-395-3734 [email protected] Media Adam Pawluk, 202-591-4063 [email protected]
